Business Wire

1. Genesis Molecular AI Unveils Pearl, A Field-Leading Foundation Model That Achieves Unprecedented Performance In Drug-Protein Structure Prediction 10/28/2025

   Genesis Molecular AI, the company pioneering the world’s leading molecular AI models for drug design and development, today announced Pearl, a generative foundation model for biomolecular structure prediction trained with novel architecture, training methodology, and large-scale synthetic data.

2. Merck Partners With Promega To Advance 3-D Cell Drug Discovery Technologies 10/28/2025

   Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery.

3. Alloy Therapeutics Announces Acquisition Of Spannerwerks, A Leading Provider Of Drug Development Consulting Services 10/23/2025

   Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the acquisition of Spannerwerks, LLC, a Seattle-based professional services firm that guides biopharmaceutical companies on the development and launch of new products.

4. Invenra Inc. And Xcellon Biologics Announce Collaboration To Advance Bispecific And Trispecific Antibody-Drug Conjugate (ADC) Development 10/22/2025

   Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs.

5. Charles River And The Francis Crick Institute Combine Expertise In Antibody-Drug Conjugate Development 10/22/2025

   Charles River Laboratories International, Inc. and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.

6. Ventus Therapeutics Enters Into A Collaboration And License Agreement With Genentech To Discover And Develop Small-Molecule Medicines Using Ventus' ReSOLVE Platform 10/21/2025

   Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover and optimize novel small-molecule candidates for challenging targets in major disease areas using Ventus’ proprietary drug discovery platform, ReSOLVE.

7. Samsung Bioepis And Phrontline Announce A Global Strategic Partnership To Advance Best-In-Class Antibody-Drug Conjugate Therapeutics For Solid Tumors 10/20/2025

   Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entered into a global collaboration agreement to develop, manufacture and commercialize two ADC assets: TJ108, bispecific and dual-payload ADC, and another asset to be named.

8. Charles River And X-Chem Announce Strategic Collaboration To Enhance Hit Identification Capabilities 10/20/2025

   Charles River Laboratories International, Inc. today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics.

9. Indivi And Clouds Of Care Partner To Advance Deep Phenotyping In Early Alzheimer's And Parkinson's Drug Development 10/15/2025

   Indivi and Clouds of Care, two independent TechBio companies, today announced a strategic partnership to advance the use of precision medicine tools in early-phase neuroscience drug development, targeting Alzheimer’s and Parkinson’s disease.

10. Syncell Expands European Market Presence To Advance Disease Research And Drug Discovery 10/14/2025

    Syncell Inc., a leader in next-generation unbiased subcellular proteomics analysis, today announced the deployment of its commercial Microscoop Mint technology at two of Europe’s foremost research institutes in proteomics and advanced technology adoption.